22nd Century Group Files 2019 Annual Report

Maintains strong balance sheet; momentum continues for Modified Risk Tobacco Product and major milestone achieved in hemp/cannabis research

News Release – March 12, 2020

View Press Release

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics

News Release – April 09, 2019

View Press Release

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

News Release – December 23, 2019

View Press Release

CDC Survey Finds Most U.S. Adults, including 80% of Smokers, Favor Lowering Nicotine Levels in Cigarettes to Make Them Less Addictive

Studies show that FDA enjoys broad consumer support to dramatically lower nicotine in cigarettes

News Release – July 12, 2019

View Press Release

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs

News Release – December 03, 2019

View Press Release

Company Mission & Profile

22nd Century Group is a plant biotechnology company focused on reducing nicotine in tobacco and creating new hemp/cannabis plants

About Us

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today